TELA TELA Bio Inc
Price (delayed)
$2.57
Market cap
$63.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.72
Enterprise value
$77.57M
TELA Bio Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is
Highlights
TELA Bio's gross profit has increased by 32% YoY and by 2% from the previous quarter
TELA's revenue is up by 32% year-on-year and by 2.5% since the previous quarter
TELA Bio's EPS has increased by 22% YoY but it has decreased by 3% from the previous quarter
The company's net income fell by 4.5% QoQ but it rose by 3.2% YoY
The equity has dropped by 93% year-on-year and by 80% since the previous quarter
The quick ratio has dropped by 57% year-on-year and by 23% since the previous quarter
Key stats
What are the main financial stats of TELA
Market
Valuations
Earnings
Shares outstanding
24.71M
Market cap
$63.51M
Enterprise value
$77.57M
Price to earnings (P/E)
N/A
Price to book (P/B)
22.08
Price to sales (P/S)
0.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.2
Revenue
$64.74M
EBIT
-$36.77M
EBITDA
-$35.9M
Free cash flow
-$44.03M
Per share
Balance sheet
Liquidity
EPS
-$1.72
Free cash flow per share
-$1.79
Book value per share
$0.12
Revenue per share
$2.63
TBVPS
$2.36
Total assets
$60.2M
Total liabilities
$57.33M
Debt
$40.82M
Equity
$2.87M
Working capital
$36.12M
Debt to equity
14.22
Current ratio
3.41
Quick ratio
2.39
Net debt/EBITDA
-0.39
Margins
Efficiency
Dividend
EBITDA margin
-55.5%
Gross margin
68.6%
Net margin
-65%
Operating margin
-71.7%
Return on assets
-56.6%
Return on equity
-252.6%
Return on invested capital
-67%
Return on capital employed
-81.3%
Return on sales
-56.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TELA stock price
How has the TELA Bio stock price performed over time
Intraday
0.39%
1 week
-2.65%
1 month
-17.36%
1 year
-70.43%
YTD
-61.18%
QTD
-45.32%
Financial performance
How have TELA Bio's revenue and profit performed over time
Revenue
$64.74M
Gross profit
$44.42M
Operating income
-$46.44M
Net income
-$42.11M
Gross margin
68.6%
Net margin
-65%
TELA Bio's gross profit has increased by 32% YoY and by 2% from the previous quarter
TELA's revenue is up by 32% year-on-year and by 2.5% since the previous quarter
TELA Bio's net margin has increased by 27% YoY
The operating income has declined by 15% year-on-year and by 2.7% since the previous quarter
Growth
What is TELA Bio's growth rate over time
Valuation
What is TELA Bio stock price valuation
P/E
N/A
P/B
22.08
P/S
0.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.2
TELA Bio's EPS has increased by 22% YoY but it has decreased by 3% from the previous quarter
The equity has dropped by 93% year-on-year and by 80% since the previous quarter
The P/B is 79% more than the 5-year quarterly average of 12.3 and 35% more than the last 4 quarters average of 16.3
TELA's price to sales (P/S) is 83% less than its 5-year quarterly average of 5.8 and 62% less than its last 4 quarters average of 2.6
TELA's revenue is up by 32% year-on-year and by 2.5% since the previous quarter
Efficiency
How efficient is TELA Bio business performance
TELA Bio's return on equity has shrunk by 63% QoQ and by 17% YoY
TELA Bio's ROS has increased by 28% YoY but it has decreased by 2.5% from the previous quarter
TELA's ROA is down by 16% since the previous quarter but it is up by 2.2% year-on-year
TELA's ROIC is up by 12% YoY but it is down by 3.6% QoQ
Dividends
What is TELA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TELA.
Financial health
How did TELA Bio financials performed over time
TELA's total assets is 5% more than its total liabilities
The quick ratio has dropped by 57% year-on-year and by 23% since the previous quarter
The current ratio has plunged by 50% YoY and by 17% from the previous quarter
The equity has dropped by 93% year-on-year and by 80% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.